PLRX PLRX
Company Profile ↓Company Overview
PLRX (PLRX) is a publicly traded company listed on with a market capitalization of $64.52M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.16.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -38.24% |
| 6 Months: | -13.22% |
| 3 Months: | -13.22% |
| 1 Month: | -10.26% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)40.14 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 43.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 28.94M | 3.60M | 4.81M | 2.17M | 1.79M | 1.61M | 1.25M | 4.99M | 1.48M | 1.33M | 248.00K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 58.94M | 45.59M | 28.27M | 23.58M | 21.77M |
| Operating Income | - | -15.74M | -13.36M | 11.01M | -16.98M | -16.66M | -22.92M | -22.90M | -27.11M | -28.21M | -29.64M | -31.95M | -42.09M | -47.33M | -47.69M | -52.39M | -60.64M | -62.01M | -58.94M | -45.59M | -28.27M | -23.58M | -21.77M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -54.92M | -42.04M | -25.05M | -23.08M | -19.78M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 799.00K | 809.00K | 815.00K | 136.00K | 0 |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -56.17M | -43.30M | -26.30M | -23.58M | -20.04M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -14.02M | -15.52M | -13.26M | 11.03M | -17.00M | -16.53M | -22.86M | -22.83M | -27.05M | -28.10M | -29.55M | -30.61M | -37.55M | -41.19M | -41.49M | -46.95M | -55.85M | -57.76M | -56.17M | -43.30M | -26.30M | -23.58M | -20.04M |
| Diluted EPS | - | -10.82 | -8.53 | 0.00 | -1.39 | -0.47 | -0.64 | -0.64 | -0.75 | -0.78 | -0.82 | -0.65 | -0.67 | -0.70 | -0.70 | -0.78 | -0.92 | -0.95 | -0.92 | -0.71 | -0.43 | -0.38 | -0.32 |
| R&D Expense | - | 13.10M | 10.78M | 13.92M | 17.54M | 16.88M | 18.53M | 19.22M | 21.05M | 20.88M | 26.34M | 24.61M | 29.27M | 33.00M | 32.34M | 37.15M | 45.62M | 47.75M | 43.44M | 32.20M | 17.94M | - | 13.58M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 57.05M | 41.82M | - | 9.69M | 1.58M | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | 136.88M | 185.72M | 228.37M | 156.37M |
| Operating Income | -1.23M | -41.65M | - | -127.20M | -184.15M | -228.37M | -156.37M |
| EBITDA | - | - | - | -120.71M | -158.23M | -205.16M | -145.09M |
| Interest Expense | - | - | - | 791.00K | 1.27M | 3.02M | 2.56M |
| Pretax Income | - | - | - | -123.32M | -161.34M | -210.30M | -149.34M |
| Tax Provision | - | - | - | - | - | - | - |
| Net Income | -631.00K | -41.53M | - | -123.32M | -161.34M | -210.30M | -149.34M |
| Diluted EPS | -4.22 | -1.95 | - | -2.94 | -2.75 | -3.47 | -2.43 |
| R&D Expense | 47.35M | 66.19M | 77.55M | 96.94M | 127.80M | 169.31M | 109.16M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 119.06M | 295.53M | - | 350.61M | 512.15M | 396.95M | 225.23M |
| Current Assets | - | - | - | - | 340.31M | 505.50M | 362.26M | 196.45M |
| Cash & Equivalents | - | 85.81M | 50.88M | - | 33.69M | 63.23M | 71.19M | 45.45M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | 2.00M | 1.98M | 0 | - | - |
| Total Liabilities | - | 9.08M | 12.46M | - | 37.27M | 38.58M | 92.87M | 44.02M |
| Current Liabilities | - | 8.17M | 11.60M | - | 23.91M | 28.52M | 33.22M | 16.36M |
| Long Term Debt | - | - | - | - | 9.93M | 10.05M | 30.21M | - |
| Total Debt | - | - | - | - | 15.81M | 11.37M | 60.19M | 29.11M |
| Total Equity | -71.47M | -76.30M | 283.06M | - | 313.34M | 473.58M | 304.08M | 181.21M |
| Shares Outstanding | - | - | - | - | 48.94M | 59.92M | 60.86M | 61.45M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -2.75M | -37.27M | - | -94.63M | -116.36M | -155.50M | -128.34M |
| Investing Cash Flow | -17.93M | -210.87M | - | -150.20M | -127.01M | 140.34M | 134.29M |
| Financing Cash Flow | 45.54M | 213.21M | - | 226.85M | 274.40M | 23.12M | -31.70M |
| Capital Expenditure | -964.00K | -1.53M | - | -1.76M | -921.00K | -3.85M | -374.00K |
| Free Cash Flow | -3.71M | -38.80M | - | -96.39M | -117.28M | -159.35M | -128.71M |
| Net Change in Cash | - | - | - | -17.98M | 31.03M | 7.95M | -25.74M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | -2.2% | -99.6% | - | -1,313.4% | -11,654.7% | - | - |
| Net Margin % | -1.1% | -99.3% | - | -1,273.3% | -10,211.1% | - | - |
| ROE % | 0.8% | -14.7% | - | -39.4% | -34.1% | -69.2% | -82.4% |
| ROCE % | -1.1% | -14.7% | - | -38.9% | -38.1% | -62.8% | -74.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PLRX
Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors
Appointments bring global oncology drug development experience and deepen Board’s operational and regulatory expertise SOUTH SAN FRANCISCO, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage…
Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced its part…
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics (Nasdaq: PLRX) today announced the dosing of the first participant in the FORTIFY Phase 1b open-label indication expansion clinical trial of PLN-101095 in c…
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment increased to 19 months Data highlighted in oral presentation at AACR’s Clinical Trials Mini Symposium Phase 1b indication…
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
First participant dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095Oral presentation at AACR 2026 featured updated data from Phase 1 trial of PLN-101095 showing deepening of confirmed responses in checkpoint inhibitor-re…
Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting
Selected for oral presentation at Clinical Trials Mini SymposiumSOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and de…
PLRX — Frequently Asked Questions
What is the current share price of PLRX?
As of 2026-08-05 17:25 PDT, PLRX trades at $1.05 on NASDAQ/NYSE. Its 52-week range is $1.04 to $1.87.
What is the market capitalisation of PLRX?
PLRX has a market capitalisation of $64.52M on NASDAQ/NYSE.
What is the P/E ratio of PLRX?
PLRX trades at a trailing price-to-earnings (P/E) ratio of -0.43. Its price-to-book (P/B) ratio is 0.36.
What is the return on equity (ROE) of PLRX?
PLRX has a return on equity (ROE) of -82.42%. Its return on capital employed (ROCE) is -74.87%.
Is PLRX a good stock to buy?
This page provides a data-driven analysis of PLRX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.